KP-104 (Vensobafusp alfa) — Interim data
Late 2026
The Company expects to report initial interim data from the IgAN basket study by year-end 2026.Source filing
JSPR biotech catalysts & pipeline
JASPER THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
briquilimab — Regulatory decision
Q1 '27
Q1 '27: Receive regulatory guidanceSource filing
KP-104 (Vensobafusp alfa) — FDA meeting
H1 2027
Based on previous positive data in treatment-naïve PNH, we are planning for an end-of-Phase 2 meeting with the FDA and plan to announce next steps in the first half of 2027.Source filing
KP-701 — IND submission
Q1 2027
In the first quarter of 2027, we expect to file a clinical trial application ("CTA") or an investigational new drug application ("IND") for Phase 1 testing, and we plan to report first-in-human data in the third quarter of 2027.Source filing
KP-104 (Vensobafusp alfa) — Full data
Q2 '27
Q2 '27: Updated data (Stage 1)Source filing
KP-701 — Initial data
Q3 2027
In the first quarter of 2027, we expect to file a clinical trial application ("CTA") or an investigational new drug application ("IND") for Phase 1 testing, and we plan to report first-in-human data in the third quarter of 2027.Source filing